| Literature DB >> 24913510 |
Christelle Ferrà1, Jaime Sanz, Miguel-Angel Díaz-Pérez, Mireia Morgades, Jorge Gayoso, José-Rafael Cabrera, Teresa Villaescusa, María-Antonia Sampol, Francesc Fernández-Avilés, Carlos Solano, Miguel Ortín, Rafael Duarte, Marian Cuesta, Inmaculada Heras, Javier de la Serna, José-María Moraleda, Cristina Barrenetxea, Marta González-Vicent, Guillermo Sanz, Josep-Maria Ribera.
Abstract
Strategies for reversing graft failure (GF) after allogeneic stem cell transplant (SCT) depend on the options available in each situation. GF was reported in 16 Spanish institutions from January 2006 to July 2011. Primary GF was defined as an absolute neutrophil count (ANC) > 0.5 × 10(9)/L not reached by day + 28 after SCT from peripheral blood (PB) or bone marrow (BM) progenitors and by day + 42 after SCT from unrelated cord blood (UCB) progenitors. Secondary GF was defined as a recurrent ANC < 0.5 × 10(9)/L. Eighty-nine patients with GF were reported, and 80 patients received a second SCT. The 5-year survival probability was 31% (95% confidence interval [CI]: 18-44%), and the incidences of non-relapse mortality and relapse estimated by competing risks were 47% (95% CI: 36-58%) and 21% (95% CI: 4-28%). The strategy adopted to treat GF was heterogeneous, and no approach could be unequivocally recommended for this situation. The prognosis of patients with GF was poor even after successful recovery from GF.Entities:
Keywords: Graft failure; hematopoietic stem cell transplant; infectious complications; outcome
Mesh：
Year: 2014 PMID： 24913510 DOI： 10.3109/10428194.2014.930849
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022